SLC23A2 and cancer: Therefore, treatment with VPA in low-SVCT2-expressing cells upregulated SVCT2 expression level, which induced intracellular AA uptake and acts as a pro-oxidant in the cancer cells by generating ROS and enhanced anticancer effect of high dose AA therapy (Figure 6).